Abstract:Importance Pancreatic ductal adenocarcinoma (PDAC) is a relatively uncommon cancer, with approximately 60 430 new diagnoses expected in 2021 in the US. The incidence of PDAC is increasing by 0.5% to 1.0% per year, and it is projected to become the second-leading cause of cancer-related mortality by 2030. Observations Effective screening is not available for PDAC, and most patients present with locally advanced (30%-35%) or metastatic (50%-55%) disease at diagnosis. A multidisciplinary management approach is recommended. Localized pancreas cancer includes resectable, borderline resectable (localized and involving major vascular structures), and locally advanced (unresectable) disease based on the degree of arterial and venous involvement by tumor, typically of the superior mesenteric vessels. For patients with resectable disease at presentation (10%-15%), surgery followed by adjuvant chemotherapy with FOLFIRINOX (fluorouracil, irinotecan, leucovorin, oxaliplatin) represents a standard therapeutic approach with an anticipated median overall survival of 54.4 months, compared with 35 months for single-agent gemcitabine (stratified hazard ratio for death, 0.64 [95% CI, 0.48-0.86]; P = .003). Neoadjuvant systemic therapy with or without radiation followed by evaluation for surgery is an accepted treatment approach for resectable and borderline resectable disease. For patients with locally advanced and unresectable disease due to extensive vascular involvement, systemic therapy followed by radiation is an option for definitive locoregional disease control. For patients with advanced (locally advanced and metastatic) PDAC, multiagent chemotherapy regimens, including FOLFIRINOX, gemcitabine/nab-paclitaxel, and nanoliposomal irinotecan/fluorouracil, all have a survival benefit of 2 to 6 months compared with a single-agent gemcitabine. For the 5% to 7% of patients with a BRCA pathogenic germline variant and metastatic PDAC, olaparib, a poly (adenosine diphosphate [ADB]-ribose) polymerase inhibitor, is a maintenance option that improves progression-free survival following initial platinum-based therapy. Conclusions and Relevance Approximately 60 000 new cases of PDAC are diagnosed per year, and approximately 50% of patients have advanced disease at diagnosis. The incidence of PDAC is increasing. Currently available cytotoxic therapies for advanced disease are modestly effective. For all patients, multidisciplinary management, comprehensive germline testing, and integrated supportive care are recommended.

Current Status of Treatment for Pancreatic Cancer in Japan and Prospects for the Future

Accurate imaging diagnosis and evaluation of pancreatic cancer

Current Status of the Diagnosis of Early-Stage Pancreatic Ductal Adenocarcinoma

Current Status and Future Prospect of Surgical Treatment for Pancreatic Cancer

Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines

Pancreatic cancer treatment: better, but a long way to go

New advances in the treatment of pancreatic carcinoma

Pancreatic Cancer: Current Multimodality Treatment Options and the Future Impact of Molecular Biological Profiling

Essential updates 2019/2020: Multimodal treatment of localized pancreatic adenocarcinoma: Current topics and updates in survival outcomes and prognostic factors

Current Limitations and Novel Perspectives in Pancreatic Cancer Treatment

An Overview of Pancreatic Cancer Diagnosis and Treatment in China: Current Landscape and Future Prospects

Reappraisal of the current resectability criteria and optimal treatment strategies for pancreatic cancer

Pancreatic Cancer: A Review of Current Treatment and Novel Therapies

Pancreatic cancer: diagnosis and treatments

Thinking in the confusion, advancing in the challenges:hotspots in the comprehensive treatment of pancreatic carcinoma

Consensus, debate, and prospective on pancreatic cancer treatments

Updates of Chemotherapy and Radiotherapy for Pancreatic Cancer

Current surgical concepts and future perspectives in the treatment of pancreatic cancer

Pancreatic Cancer: A Review.

Current status of the combined therapy for pancreatic cancer

Current status of endoscopic ultrasound‐guided antitumor treatment for pancreatic cancer